Ratings GENinCode Plc

Equities

GENI

GB00BL97B504

Delayed London S.E. Other stock markets 07:04:34 2024-05-13 EDT			5-day change	1st Jan Change
8.306 ^GBX	-13.70%		+5.47%	+58.21%

04-04	GENinCode Plc Announces Publication by the American Journal of Preventive Cardiology of A Study on 'Polygenic Risk and Incident Heart Disease in a Large Multiethnic Cohort	CI
03-21	GENinCode says ROCA recommended as ovarian cancer risk test in England	AN

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company has insufficient levels of profitability.
The company's "enterprise value to sales" ratio is among the highest in the world.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
Revenue estimates are regularly revised downwards for the current and coming years.
Over the past four months, analysts' average price target has been revised downwards significantly.
Over the past twelve months, analysts' opinions have been revised negatively.

Ratings chart - Surperformance

Sector: Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
GENINCODE PLC	+58.21%	21.32M		-
BIOMÉRIEUX	-2.58%	12.64B		B+
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-0.47%	8.46B		B-
DIASORIN S.P.A.	+8.38%	5.66B		B
LANTHEUS HOLDINGS, INC.	+25.20%	5.27B		C
AUTOBIO DIAGNOSTICS CO., LTD.	-2.03%	4.49B		C
10X GENOMICS, INC.	-50.80%	3.11B		D+
ANDON HEALTH CO., LTD.	+19.30%	2.87B	-	-
MYRIAD GENETICS, INC.	+32.34%	2.31B		C
GUANGZHOU WONDFO BIOTECH CO.,LTD	-3.55%	1.89B		D+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes